Seeking Alpha

Mela Sciences (MELA) +111% after an FDA panel narrowly backed its experimental skin cancer...

Mela Sciences (MELA) +111% after an FDA panel narrowly backed its experimental skin cancer detection device late Thursday. Some panelists said MELA's MelaFind device could help save lives, while others expressed doubts that it could help doctors detect cancers. Earlier this week, FDA staffers said MelaFind was not studied adequately, could be a health risk, and urged a new clinical study.
Comments (1)
  • jrusso9722
    , contributor
    Comments (97) | Send Message
     
    Like everything in life, we'll take one day at a time. People who doubt MelaFind, obviously don't have melanoma. Get real, and put the shoe on the other foot. If you are suspicious for, or have had a melanoma leison, you, me, everyone will want a MelaFind scan."Could be a health risk" statement smacks of an area that I don't want to go into. FDA Review Panel got it right! on 11/18/10.
    19 Nov 2010, 01:53 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs